Medtech firm Synthes has admitted it is courting a takeover deal from a pharmaceutical giant with majority shareholder Hansjrg Wyss prepared to hand over the reins.
'%20id='ico-down'%20stroke='%23000000'%20stroke-width='1.5'%3e%3cg%20transform='translate(1092.250000,%20254.750000)'%3e%3cpolyline%20id='Path-2-Copy-4'%20transform='translate(5.500000,%202.750000)%20scale(1,%20-1)%20rotate(-180.000000)%20translate(-5.500000,%20-2.750000)%20'%20points='0%200%205.5%205.5%2011%200'%3e%3c/polyline%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Expatica news
Expatica news
Medtech firm Synthes has admitted it is courting a takeover deal from a pharmaceutical giant with majority shareholder Hansjrg Wyss prepared to hand over the reins.